

Company Overview


T-NanoBio Therapeutics, Inc., a Delaware corporation, is a new emerging biotechnology company developing an innovative therapeutic platform based on transformable peptide nanoparticles. The technology consists of bispecific peptides that self-assemble, targeting tumor cells and cytotoxic T-cells, which result in a potent anti-tumor response in multiple oncology indications. Our nano immuno-engager (“NIE”) platform can harness a patient’s own immune system against cancer, while our HER2+ platform will offer a new treatment paradigm for treating HER2+ tumors. The company has sufficient data to progress into pharma/tox studies within 6 months of funding, followed by an IND filing which is expected to be in 18 months. The Company is comprised of a very senior and seasoned team with expertise in all areas of science, clinical studies, finance, business, commercialization, CMC and corporate development with over 120 years of combined experience.

Platform Highlights

- Demonstrated conversion of ‘cold’ to ‘hot’ tumors in a syngeneic cancer model, creating the ideal clinical setting for immune checkpoint inhibitors.
- In combination with anti-PD-1 antibody, the therapy was able to cure lung and breast cancer bearing mice, resulting in 100% overall survival in mice.
- Induced immune memory response against future implantation of breast cancer cells.
- HER2+ targeted transformable nanoparticles as a monotherapy have demonstrated curing HER2+ breast cancer in mice.
- Exclusively licensing technology from the University of California Davis Cancer Center.


How does the Nano Immuno-Engager (“NIE”) work in Cancer Immunotherapy?

Transformable Nano Particles (NP)



Self Assembly


NIE-NPs






IV Injection



- 1) NIE delivered to the tumor
- 2) NIE transformed to nanofibrils at the tumor cell membrane
- 3) Nanofibrillar network at the TME captures T_{eff} cells
- 4) Allows sustained release of resiquimod for immunomodulation



Pipeline: Advancing Transformable Peptide Nanoparticle Programs

Product	Indication	Discovery	IND-enabling	Clinical
NIE	NSCLC, Melanoma, Breast, HNSCC			
HER2+	Solid HER2+ (Breast, Gastric)			
Combination (NIE and HER2+)	Solid HER2+ Tumors			

Key US Cancer Statistics


- NSCLC: 238,000 new cases of lung cancer with 80-85% diagnosed annually as NSCLC.
- Melanoma: 97,000 new melanomas will be diagnosed annually.
- Breast Cancer: 297,000 new cases of breast cancer will be diagnosed annually
- Breast HER2+: 20% of annually diagnosed breast cancer patients.

Nano Immuno-Engager: Delivers a Potent Anti-tumor Response in Mice when administered with an anti-PD-1 antibody

Immune System Reset

Key Parameters Analyzed

- Eliminates syngeneic breast cancer.
- Resiquimod released from nanofibrils re-educates tumor associated macrophages M2 → M1.
- Increase in CD8+ T Killer Cells.



M2
Anti-immune

M1
Pro-Inflammatory

Leadership

Anthony E. Maida III, PhD

Co-Founder, Chief Executive Officer

Kit S. Lam, MD, PhD

Co-Founder, Chair of Scientific Advisory Board

Tim J. Obara

Co-Founder, Chief Business Officer

Board Members

- o Anthony E. Maida III PhD (Chair)
- o William Ashton
- o Timothy J. Obara
- o Kit S. Lam, MD, PhD
- o Richard B. Slansky

Scientific Advisers

- o Kit S. Lam, MD, PhD (Chair)
- o David Gandara, MD
- o Jerome Galon, PhD
- o Primo Lara, MD
- o Jose Lutzky, MD
- o Kim Margolin, MD
- o James Talmadge, PhD